Our empagliflozin results are consistence with post hoc of DAPA-CKD [30], EMPA-KIDNEY [27], and recent meta-analysis evaluated the cardiorenal protective effects of SGLT2 inhibitors including their large trials [14]. Here, SLC5A2 is linked to chronic kidney disease.